AbbVie ends deal for Infinity's duvelisib

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) said AbbVie Inc. (NYSE:ABBV) ended the companies' 2014 deal to co-develop oncology candidate duvelisib ( IPI-145), and returned its rights to Infinity.

Earlier this month, Infinity reported results of a Phase II study to treat indolent non-Hodgkin's lymphoma (NHL) that showed duvelisib's clinical benefit was smaller than expected. At the time, the company said it and AbbVie would discuss next steps for the compound and their collaboration (see BioCentury Extra, June 14). ...